Natural killer cells in clinical development as non-engineered, engineered, and combination therapiesNina Lamers-Kok, Monica Raimo, Denise Panella et al.|Journal of Hematology & Oncology|2022Cited by 178
245 Cord blood CD34<sup>+</sup> stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ natural killer cells which display selective cytotoxicity against B-cell leukemiaMonica Raimo, Adil Deniz Duru, Amanda van Vliet et al.|Regular and Young Investigator Award Abstracts|2022Cited by 0
Additional file 2 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapiesNina Lamers-Kok, Monica Raimo, Denise Panella et al.|Figshare|2022Cited by 0
Additional file 4 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapiesNina Lamers-Kok, Monica Raimo, Anna‐Maria Georgoudaki et al.|Figshare|2022Cited by 0
Additional file 1 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapiesNina Lamers-Kok, Monica Raimo, Denise Panella et al.|Figshare|2022Cited by 0